Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection
- Autores
- Flor, Noelia; García, María Inés; Molineri, Ana Ines; Botasso, Oscar; Diez, Cristina; Veaute, Carolina
- Año de publicación
- 2023
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- The COVID-19 pandemic remained worldwide for almost three years, but little is known about the dynamics of humoral immune response to the third dose over time and its protection from infection. Our aim was to assess the humoral immune response after the third dose of the different vaccines administered to SARS-CoV-2 naive and previously infected individuals, and its correlation with protection in an academic community. For each person studied (185), three blood samples were taken between December 2021 and July 2022, one month apart. Anti-S antibodies were quantified by ELISA, while anti-N antibody levels were determined by ECLIA. Most of the participants had received two doses of viral vector-based, mRNA-based and virus-inactivated vaccines. Although anti-N antibody levels revealed that 80% of the individuals had been exposed to the virus before or during the study, only 42% reported having been diagnosed. When anti-S IgG levels were measured 3–5 months after the second dose of any vaccine, they were higher in those previously infected individuals. The same results were observed for anti-N IgG levels in those who received 2 doses of the virus-inactivated vaccine. When analyzing the dynamics of anti-S antibodies we observed that, although positive IgG antibody levels were detected 5–6 months after the second dose administration, those observed 30–60 days after the third dose were significantly higher and remained so for at least 8 months. Higher levels of anti-S IgG antibodies at the first sampling were associated with a lower incidence of subse quent infection. The same association was seen in people who received the booster compared with those who received two doses. This study provides further evidence that anti-S IgG antibodies remained at high levels over time, and both anti-S levels and the third dose of anti-SARS-CoV-2 vaccine correlate with protection against the infection. It also shows that infection acts as a booster of immunization, increasing levels of both anti-N and anti-S IgG.
EEA Rafaela
Fil: Flor, Noelia. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; Argentina
Fil: García, María Ines. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; Argentina
Fil: Molineri, Ana Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina
Fil: Molineri, Ana Ines. Consejo Nacional de Ciencia y Tecnología (CONICET). Instituto de Investigación de la Cadena Láctea (IDICAL); Argentina
Fil: Molineri, Ana Ines. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Instituto de Investigación de la Cadena Láctea (IDICAL); Argentina
Fil: Botasso, Oscar. Universidad Nacional de Rosario; Argentina
Fil: Botasso, Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Instituto de Inmunología clínica y Experimental de Rosario (IDICER); Argentina
Fil: Diez, Cristina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Biología Molecular e Inmunología Aplicadas; Argentina
Fil: Veaute; Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; Argentina
Fil: Veaute, Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Biología Molecular e Inmunología Aplicadas; Argentina - Fuente
- Vaccine 41 (48) : 7206-7211 (2023)
- Materia
-
Vacuna
Inmunidad
COVID-19
Coronavirus del síndrome respiratorio agudo grave 2
Vaccines
Immunity
Severe acute respiratory syndrome coronavirus 2
Serovigilancia
SARS-CoV2
Serosurveillance - Nivel de accesibilidad
- acceso restringido
- Condiciones de uso
- http://creativecommons.org/licenses/by-nc-sa/4.0/
- Repositorio
- Institución
- Instituto Nacional de Tecnología Agropecuaria
- OAI Identificador
- oai:localhost:20.500.12123/16258
Ver los metadatos del registro completo
id |
INTADig_0d8c87cead18eb95752bb906dcae0384 |
---|---|
oai_identifier_str |
oai:localhost:20.500.12123/16258 |
network_acronym_str |
INTADig |
repository_id_str |
l |
network_name_str |
INTA Digital (INTA) |
spelling |
Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infectionFlor, NoeliaGarcía, María InésMolineri, Ana InesBotasso, OscarDiez, CristinaVeaute, CarolinaVacunaInmunidadCOVID-19Coronavirus del síndrome respiratorio agudo grave 2VaccinesImmunitySevere acute respiratory syndrome coronavirus 2SerovigilanciaSARS-CoV2SerosurveillanceThe COVID-19 pandemic remained worldwide for almost three years, but little is known about the dynamics of humoral immune response to the third dose over time and its protection from infection. Our aim was to assess the humoral immune response after the third dose of the different vaccines administered to SARS-CoV-2 naive and previously infected individuals, and its correlation with protection in an academic community. For each person studied (185), three blood samples were taken between December 2021 and July 2022, one month apart. Anti-S antibodies were quantified by ELISA, while anti-N antibody levels were determined by ECLIA. Most of the participants had received two doses of viral vector-based, mRNA-based and virus-inactivated vaccines. Although anti-N antibody levels revealed that 80% of the individuals had been exposed to the virus before or during the study, only 42% reported having been diagnosed. When anti-S IgG levels were measured 3–5 months after the second dose of any vaccine, they were higher in those previously infected individuals. The same results were observed for anti-N IgG levels in those who received 2 doses of the virus-inactivated vaccine. When analyzing the dynamics of anti-S antibodies we observed that, although positive IgG antibody levels were detected 5–6 months after the second dose administration, those observed 30–60 days after the third dose were significantly higher and remained so for at least 8 months. Higher levels of anti-S IgG antibodies at the first sampling were associated with a lower incidence of subse quent infection. The same association was seen in people who received the booster compared with those who received two doses. This study provides further evidence that anti-S IgG antibodies remained at high levels over time, and both anti-S levels and the third dose of anti-SARS-CoV-2 vaccine correlate with protection against the infection. It also shows that infection acts as a booster of immunization, increasing levels of both anti-N and anti-S IgG.EEA RafaelaFil: Flor, Noelia. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; ArgentinaFil: García, María Ines. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; ArgentinaFil: Molineri, Ana Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; ArgentinaFil: Molineri, Ana Ines. Consejo Nacional de Ciencia y Tecnología (CONICET). Instituto de Investigación de la Cadena Láctea (IDICAL); ArgentinaFil: Molineri, Ana Ines. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Instituto de Investigación de la Cadena Láctea (IDICAL); ArgentinaFil: Botasso, Oscar. Universidad Nacional de Rosario; ArgentinaFil: Botasso, Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Instituto de Inmunología clínica y Experimental de Rosario (IDICER); ArgentinaFil: Diez, Cristina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Biología Molecular e Inmunología Aplicadas; ArgentinaFil: Veaute; Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; ArgentinaFil: Veaute, Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Biología Molecular e Inmunología Aplicadas; ArgentinaElsevier2023-12-15T17:58:19Z2023-12-15T17:58:19Z2023-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/16258https://www.sciencedirect.com/science/article/abs/pii/S0264410X230122151873-25180264-410Xhttps://doi.org/10.1016/j.vaccine.2023.10.038Vaccine 41 (48) : 7206-7211 (2023)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/restrictedAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)2025-09-04T09:50:08Zoai:localhost:20.500.12123/16258instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-09-04 09:50:08.552INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse |
dc.title.none.fl_str_mv |
Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection |
title |
Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection |
spellingShingle |
Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection Flor, Noelia Vacuna Inmunidad COVID-19 Coronavirus del síndrome respiratorio agudo grave 2 Vaccines Immunity Severe acute respiratory syndrome coronavirus 2 Serovigilancia SARS-CoV2 Serosurveillance |
title_short |
Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection |
title_full |
Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection |
title_fullStr |
Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection |
title_full_unstemmed |
Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection |
title_sort |
Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection |
dc.creator.none.fl_str_mv |
Flor, Noelia García, María Inés Molineri, Ana Ines Botasso, Oscar Diez, Cristina Veaute, Carolina |
author |
Flor, Noelia |
author_facet |
Flor, Noelia García, María Inés Molineri, Ana Ines Botasso, Oscar Diez, Cristina Veaute, Carolina |
author_role |
author |
author2 |
García, María Inés Molineri, Ana Ines Botasso, Oscar Diez, Cristina Veaute, Carolina |
author2_role |
author author author author author |
dc.subject.none.fl_str_mv |
Vacuna Inmunidad COVID-19 Coronavirus del síndrome respiratorio agudo grave 2 Vaccines Immunity Severe acute respiratory syndrome coronavirus 2 Serovigilancia SARS-CoV2 Serosurveillance |
topic |
Vacuna Inmunidad COVID-19 Coronavirus del síndrome respiratorio agudo grave 2 Vaccines Immunity Severe acute respiratory syndrome coronavirus 2 Serovigilancia SARS-CoV2 Serosurveillance |
dc.description.none.fl_txt_mv |
The COVID-19 pandemic remained worldwide for almost three years, but little is known about the dynamics of humoral immune response to the third dose over time and its protection from infection. Our aim was to assess the humoral immune response after the third dose of the different vaccines administered to SARS-CoV-2 naive and previously infected individuals, and its correlation with protection in an academic community. For each person studied (185), three blood samples were taken between December 2021 and July 2022, one month apart. Anti-S antibodies were quantified by ELISA, while anti-N antibody levels were determined by ECLIA. Most of the participants had received two doses of viral vector-based, mRNA-based and virus-inactivated vaccines. Although anti-N antibody levels revealed that 80% of the individuals had been exposed to the virus before or during the study, only 42% reported having been diagnosed. When anti-S IgG levels were measured 3–5 months after the second dose of any vaccine, they were higher in those previously infected individuals. The same results were observed for anti-N IgG levels in those who received 2 doses of the virus-inactivated vaccine. When analyzing the dynamics of anti-S antibodies we observed that, although positive IgG antibody levels were detected 5–6 months after the second dose administration, those observed 30–60 days after the third dose were significantly higher and remained so for at least 8 months. Higher levels of anti-S IgG antibodies at the first sampling were associated with a lower incidence of subse quent infection. The same association was seen in people who received the booster compared with those who received two doses. This study provides further evidence that anti-S IgG antibodies remained at high levels over time, and both anti-S levels and the third dose of anti-SARS-CoV-2 vaccine correlate with protection against the infection. It also shows that infection acts as a booster of immunization, increasing levels of both anti-N and anti-S IgG. EEA Rafaela Fil: Flor, Noelia. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; Argentina Fil: García, María Ines. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; Argentina Fil: Molineri, Ana Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina Fil: Molineri, Ana Ines. Consejo Nacional de Ciencia y Tecnología (CONICET). Instituto de Investigación de la Cadena Láctea (IDICAL); Argentina Fil: Molineri, Ana Ines. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Instituto de Investigación de la Cadena Láctea (IDICAL); Argentina Fil: Botasso, Oscar. Universidad Nacional de Rosario; Argentina Fil: Botasso, Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Instituto de Inmunología clínica y Experimental de Rosario (IDICER); Argentina Fil: Diez, Cristina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Biología Molecular e Inmunología Aplicadas; Argentina Fil: Veaute; Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; Argentina Fil: Veaute, Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Biología Molecular e Inmunología Aplicadas; Argentina |
description |
The COVID-19 pandemic remained worldwide for almost three years, but little is known about the dynamics of humoral immune response to the third dose over time and its protection from infection. Our aim was to assess the humoral immune response after the third dose of the different vaccines administered to SARS-CoV-2 naive and previously infected individuals, and its correlation with protection in an academic community. For each person studied (185), three blood samples were taken between December 2021 and July 2022, one month apart. Anti-S antibodies were quantified by ELISA, while anti-N antibody levels were determined by ECLIA. Most of the participants had received two doses of viral vector-based, mRNA-based and virus-inactivated vaccines. Although anti-N antibody levels revealed that 80% of the individuals had been exposed to the virus before or during the study, only 42% reported having been diagnosed. When anti-S IgG levels were measured 3–5 months after the second dose of any vaccine, they were higher in those previously infected individuals. The same results were observed for anti-N IgG levels in those who received 2 doses of the virus-inactivated vaccine. When analyzing the dynamics of anti-S antibodies we observed that, although positive IgG antibody levels were detected 5–6 months after the second dose administration, those observed 30–60 days after the third dose were significantly higher and remained so for at least 8 months. Higher levels of anti-S IgG antibodies at the first sampling were associated with a lower incidence of subse quent infection. The same association was seen in people who received the booster compared with those who received two doses. This study provides further evidence that anti-S IgG antibodies remained at high levels over time, and both anti-S levels and the third dose of anti-SARS-CoV-2 vaccine correlate with protection against the infection. It also shows that infection acts as a booster of immunization, increasing levels of both anti-N and anti-S IgG. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-12-15T17:58:19Z 2023-12-15T17:58:19Z 2023-10 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/20.500.12123/16258 https://www.sciencedirect.com/science/article/abs/pii/S0264410X23012215 1873-2518 0264-410X https://doi.org/10.1016/j.vaccine.2023.10.038 |
url |
http://hdl.handle.net/20.500.12123/16258 https://www.sciencedirect.com/science/article/abs/pii/S0264410X23012215 https://doi.org/10.1016/j.vaccine.2023.10.038 |
identifier_str_mv |
1873-2518 0264-410X |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/restrictedAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) |
eu_rights_str_mv |
restrictedAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
Vaccine 41 (48) : 7206-7211 (2023) reponame:INTA Digital (INTA) instname:Instituto Nacional de Tecnología Agropecuaria |
reponame_str |
INTA Digital (INTA) |
collection |
INTA Digital (INTA) |
instname_str |
Instituto Nacional de Tecnología Agropecuaria |
repository.name.fl_str_mv |
INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria |
repository.mail.fl_str_mv |
tripaldi.nicolas@inta.gob.ar |
_version_ |
1842341416919891968 |
score |
12.623145 |